• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Rallybio Corporation (Amendment)

    2/6/23 4:32:59 PM ET
    $RLYB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RLYB alert in real time by email
    SC 13G/A 1 d356328dsc13ga.htm SC 13G/A SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

     

    Rallybio Corporation

    (Name of Issuer)

    Common Stock, $0.0001 par value per share

    (Title of Class of Securities)

    75120L100

    (CUSIP Number)

    December 31, 2022

    (Date of Event which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☒ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 75120L100   13G

     

     

      1.    

      NAMES OF REPORTING PERSONS

     

      New Leaf Ventures III, L.P.

      2.  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

      (a)  ☐        (b)  ☒

      3.  

      SEC USE ONLY

     

      4.  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5.    

      SOLE VOTING POWER

     

      0

       6.  

      SHARED VOTING POWER

     

      2,147,757 (1)

       7.  

      SOLE DISPOSITIVE POWER

     

      0

       8.  

      SHARED DISPOSITIVE POWER

     

      2,147,757 (1)

      9.    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      2,147,757 (1)

    10.  

      CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)

     

      ☐

    11.  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

      5.8% (2)

    12.  

      TYPE OF REPORTING PERSON (see instructions)

     

      PN

     

    (1)

    All such shares are held of record by NLV-III (as defined in Item 2(a) of the Original Schedule 13G). NLVM-III (as defined in Item 2(a) of the Original Schedule 13G) is the general partner of NLVA-III (as defined in Item 2(a) of the Original Schedule 13G), which is the general partner of NLV-III. Each of NLVM-III and NLVA-III may be deemed to have voting, investment and dispositive power with respect to these securities. Ronald Hunt, a member of the Issuer’s board of directors, and Vijay Lathi are the managing members of NLVM-III and may each be deemed to share voting, investment and dispositive power with respect to these securities.

    (2)

    Based on 37,091,399 shares of the Issuer’s Common Stock outstanding immediately after the Issuer’s public offering (excluding the underwriter’s option to purchase an additional 1,250,000 shares), as reported in the Issuer’s prospectus on Form 424(b)(5) and filed with the Securities and Exchange Commission (the “Commission”) on November 14, 2022 (the “Prospectus”).


    CUSIP No. 75120L100   13G

     

     

      1.    

      NAMES OF REPORTING PERSONS

     

      New Leaf Venture Associates III, L.P.

      2.  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

      (a)  ☐        (b)  ☒

      3.  

      SEC USE ONLY

     

      4.  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5.    

      SOLE VOTING POWER

     

      0

       6.  

      SHARED VOTING POWER

     

      2,147,757 (1)

       7.  

      SOLE DISPOSITIVE POWER

     

      0

       8.  

      SHARED DISPOSITIVE POWER

     

      2,147,757 (1)

      9.    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      2,147,757 (1)

    10.  

      CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)

     

      ☐

    11.  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

      5.8% (2)

    12.  

      TYPE OF REPORTING PERSON (see instructions)

     

      PN

     

    (1)

    All such shares are held of record by NLV-III. NLVM-III is the general partner of NLVA-III, which is the general partner of NLV-III. Each of NLVM-III and NLVA-III may be deemed to have voting, investment and dispositive power with respect to these securities. Ronald Hunt, a member of the Issuer’s board of directors, and Vijay Lathi are the managing members of NLVM-III and may each be deemed to share voting, investment and dispositive power with respect to these securities.

    (2)

    Based on 37,091,399 shares of the Issuer’s Common Stock outstanding immediately following the Issuer’s public offering, as reported in the Prospectus.


    CUSIP No. 75120L100   13G

     

     

      1.    

      NAMES OF REPORTING PERSONS

     

      New Leaf Venture Management III, L.L.C.

      2.  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

      (a)  ☐        (b)  ☒

      3.  

      SEC USE ONLY

     

      4.  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5.    

      SOLE VOTING POWER

     

      0

       6.  

      SHARED VOTING POWER

     

      2,147,757 (1)

       7.  

      SOLE DISPOSITIVE POWER

     

      0

       8.  

      SHARED DISPOSITIVE POWER

     

      2,147,757 (1)

      9.    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      2,147,757 (1)

    10.  

      CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)

     

      ☐

    11.  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

      5.8% (2)

    12.  

      TYPE OF REPORTING PERSON (see instructions)

     

      00

     

    (1)

    All such shares are held of record by NLV-III. NLVM-III is the general partner of NLVA-III, which is the general partner of NLV-III. Each of NLVM-III and NLVA-III may be deemed to have voting, investment and dispositive power with respect to these securities. Ronald Hunt, a member of the Issuer’s board of directors, and Vijay Lathi are the managing members of NLVM-III and may each be deemed to share voting, investment and dispositive power with respect to these securities.

    (2)

    Based on 37,091,399 shares of the Issuer’s Common Stock outstanding immediately following the Issuer’s public offering, as reported in the Prospectus.


    CUSIP No. 75120L100   13G

     

     

      1.    

      NAMES OF REPORTING PERSONS

     

      New Leaf Biopharma Opportunities II, L.P.

      2.  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

      (a)  ☐        (b)  ☒

      3.  

      SEC USE ONLY

     

      4.  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5.    

      SOLE VOTING POWER

     

      0

       6.  

      SHARED VOTING POWER

     

      1,153,846 (1)

       7.  

      SOLE DISPOSITIVE POWER

     

      0

       8.  

      SHARED DISPOSITIVE POWER

     

      1,153,846 (1)

      9.    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      1,153,846 (1)

    10.  

      CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)

     

      ☐

    11.  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

      3.1% (2)

    12.  

      TYPE OF REPORTING PERSON (see instructions)

     

      PN

     

    (1)

    All such shares are held of record by NL BPO-II (as defined in Item 2(a) of the Original Schedule 13G). NL BPOM-II (as defined in Item 2(a) of the Original Schedule 13G) is the general partner of NL BPOA-II (as defined in Item 2(a) of the Original Schedule 13G), which is the general partner of NL BPO-II. Each of NL BPOM-II and NL BPOA-II may be deemed to have voting, investment and dispositive power with respect to these securities. Ronald Hunt, a member of the Issuer’s board of directors, and Vijay Lathi are the managing members of NL BPOM-II and may each be deemed to share voting, investment and dispositive power with respect to these securities.

    (2)

    Based on 37,091,399 shares of the Issuer’s Common Stock outstanding immediately following the Issuer’s public offering, as reported in the Prospectus.


    CUSIP No. 75120L100   13G

     

     

      1.    

      NAMES OF REPORTING PERSONS

     

      New Leaf BPO Associates II, L.P.

      2.  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

      (a)  ☐        (b)  ☒

      3.  

      SEC USE ONLY

     

      4.  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5.    

      SOLE VOTING POWER

     

      0

       6.  

      SHARED VOTING POWER

     

      1,153,846 (1)

       7.  

      SOLE DISPOSITIVE POWER

     

      0

       8.  

      SHARED DISPOSITIVE POWER

     

      1,153,846 (1)

      9.    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      1,153,846 (1)

    10.  

      CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)

     

      ☐

    11.  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

      3.1% (2)

    12.  

      TYPE OF REPORTING PERSON (see instructions)

     

      PN

     

    (1)

    All such shares are held of record by NL BPO-II. NL BPOM-II is the general partner of NL BPOA-II, which is the general partner of NL BPO-II. Each of NL BPOM-II and NL BPOA-II may be deemed to have voting, investment and dispositive power with respect to these securities. Ronald Hunt, a member of the Issuer’s board of directors, and Vijay Lathi are the managing members of NL BPOM-II and may each be deemed to share voting, investment and dispositive power with respect to these securities.

    (2)

    Based on 37,091,399 shares of the Issuer’s Common Stock outstanding immediately following the Issuer’s public offering, as reported in the Prospectus.


    CUSIP No. 75120L100   13G

     

     

      1.    

      NAMES OF REPORTING PERSONS

     

      New Leaf BPO Management II, L.L.C.

      2.  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

      (a)  ☐        (b)  ☒

      3.  

      SEC USE ONLY

     

      4.  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5.    

      SOLE VOTING POWER

     

      0

       6.  

      SHARED VOTING POWER

     

      1,153,846 (1)

       7.  

      SOLE DISPOSITIVE POWER

     

      0

       8.  

      SHARED DISPOSITIVE POWER

     

      1,153,846 (1)

      9.    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      1,153,846 (1)

    10.  

      CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)

     

      ☐

    11.  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

      3.1% (2)

    12.  

      TYPE OF REPORTING PERSON (see instructions)

     

      OO

     

    (1)

    All such shares are held of record by NL BPO-II. NL BPOM-II is the general partner of NL BPOA-II, which is the general partner of NL BPO-II. Each of NL BPOM-II and NL BPOA-II may be deemed to have voting, investment and dispositive power with respect to these securities. Ronald Hunt, a member of the Issuer’s board of directors, and Vijay Lathi are the managing members of NL BPOM-II and may each be deemed to share voting, investment and dispositive power with respect to these securities.

    (2)

    Based on 37,091,399 shares of the Issuer’s Common Stock outstanding immediately following the Issuer’s public offering, as reported in the Prospectus.


    CUSIP No. 75120L100   13G

     

     

      1.    

      NAMES OF REPORTING PERSONS

     

      Ronald Hunt

      2.  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

      (a)  ☐        (b)  ☒

      3.  

      SEC USE ONLY

     

      4.  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      United States of America

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5.    

      SOLE VOTING POWER

     

    21,532 shares of Common Stock underlying fully vested stock options, or stock options that fully vest within 60 days of December 31, 2022, owned directly by Hunt.

       6.  

      SHARED VOTING POWER

     

      3,301,603 (1)

       7.  

      SOLE DISPOSITIVE POWER

     

    21,532 shares of Common Stock underlying fully vested stock options, or stock options that fully vest within 60 days of December 31, 2022, owned directly by Hunt.

       8.  

      SHARED DISPOSITIVE POWER

     

      3,301,603 (1)

      9.    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      3,323,135 (1)

    10.  

      CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)

     

      ☐

    11.  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

      8.9% (2)

    12.  

      TYPE OF REPORTING PERSON (see instructions)

     

      IN

     

    (1)

    Consists of (i) 2,147,757 shares of the Issuer’s Common Stock held by NLV-III and (ii) 1,153,846 shares of the Issuer’s Common Stock held by NL BPO-II. NLVM-III is the general partner of NLVA-III, which is the general partner of NLV-III. Each of NLVM-III and NLVA-III may be deemed to have voting, investment and dispositive power with respect to the shares held by NLV-III. NL BPOM-II is the general partner of NL BPOA-II, which is the general partner of NL BPO-II. Each of NL BPOM-II and NL BPOA-II may be deemed to have voting, investment and dispositive power with respect to the shares held by NL BPO-II. Ronald Hunt, a member of the Issuer’s board of directors, and Vijay Lathi are managing members of each of NLVM-III and NL BPOM-II and may be deemed to have voting, investment and dispositive power with respect to the shares held by each of NLV-III and NL BPO-II.

    (2)

    Based on 37,112,931 shares of the Issuer’s Common Stock, calculated as follows (i) 37,091,399 shares of the Issuer’s Common Stock outstanding immediately following the Issuer’s public offering, as reported in the Prospectus plus (ii) 21,532 shares of the Issuer’s Common Stock underlying fully vested stock options or options that will become fully vested within 60 days of December 31, 2022, granted to Hunt in his capacity as a member of the Issuer’s board of directors.


    CUSIP No. 75120L100   13G

     

     

      1.    

      NAMES OF REPORTING PERSONS

     

      Vijay Lathi

      2.  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

      (a)  ☐        (b)  ☒

      3.  

      SEC USE ONLY

     

      4.  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      United States of America

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5.    

      SOLE VOTING POWER

     

      0

       6.  

      SHARED VOTING POWER

     

      3,301,603 (1)

       7.  

      SOLE DISPOSITIVE POWER

     

      0

       8.  

      SHARED DISPOSITIVE POWER

     

      3,301,603 (1)

      9.    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      3,301,603 (1)

    10.  

      CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)

     

      ☐

    11.  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

      8.9% (2)

    12.  

      TYPE OF REPORTING PERSON (see instructions)

     

      IN

     

    (1)

    Consists of (i) 2,147,757 shares of the Issuer’s Common Stock held by NLV-III and (ii) 1,153,846 shares of the Issuer’s Common Stock held by NL BPO-II. NLVM-III is the general partner of NLVA-III, which is the general partner of NLV-III. Each of NLVM-III and NLVA-III may be deemed to have voting, investment and dispositive power with respect to the shares held by NLV-III. NL BPOM-II is the general partner of NL BPOA-II, which is the general partner of NL BPO-II. Each of NL BPOM-II and NL BPOA-II may be deemed to have voting, investment and dispositive power with respect to the shares held by NL BPO-II. Ronald Hunt, a member of the Issuer’s board of directors, and Vijay Lathi are managing members of each of NLVM-III and NL BPOM-II and may be deemed to have voting, investment and dispositive power with respect to the shares held by each of NLV-III and NL BPO-II.

    (2)

    Based on 37,091,399 shares of the Issuer’s Common Stock outstanding immediately following the Issuer’s public offering, as reported in the Prospectus.


    CUSIP No. 75120L100   13G

     

    Introductory Note: This Amendment No. 1 (the “Amendment”) amends and supplements the Schedule 13G originally filed by the Reporting Persons with the Commission on February 11, 2022 (the “Original Schedule 13G”). Only those items that are hereby reported are amended; all other items reported in the Original Schedule 13G remain unchanged. Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable. Capitalized terms not defined in this Amendment have the meanings ascribed to them in the Original Schedule 13G.

     

    Item 4.

    Ownership.

     

      (a)

    Amount beneficially owned:

    See Row 9 of the cover page for each Reporting Person.*

     

      (b)

    Percent of class:

    See Row 11 of the cover page for each Reporting Person and the corresponding footnotes.*

     

      (c)

    Number of shares as to which the person has:

     

      (i)

    Sole power to vote or to direct the vote

    See Row 5 of the cover page for each Reporting Person and the corresponding footnotes.*

     

      (ii)

    Shared power to vote or to direct the vote

    See Row 6 of the cover page for each Reporting Person and the corresponding footnotes.*

     

      (iii)

    Sole power to dispose or to direct the disposition of

    See Row 7 of the cover page for each Reporting Person and the corresponding footnotes.*

     

      (iv)

    Shared power to dispose or to direct the disposition of

    See Row 8 of the cover page for each Reporting Person and the corresponding footnotes.*

     

    *

    Except to the extent of his, her or its pecuniary interest therein, each Reporting Person disclaims beneficial ownership of such shares of Common Stock, except for the shares, if any, such Reporting Person holds of record.


    CUSIP No. 75120L100   13G

     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: February 6, 2023

     

    NEW LEAF VENTURES III, L.P.
    By:   New Leaf Venture Associates III, L.P.
    Its:   General Partner
    By:   New Leaf Venture Management III, L.L.C.
    Its:   General Partner
    By:   /s/ Craig L. Slutzkin
      Craig L. Slutzkin
    Its:   Chief Financial Officer
    NEW LEAF VENTURE ASSOCIATES III, L.P.
    By:   New Leaf Venture Management III, L.L.C.
    Its:   General Partner
    By:   /s/ Craig L. Slutzkin
      Craig L. Slutzkin
    Its:   Chief Financial Officer
    NEW LEAF VENTURE MANAGEMENT III, L.L.C.
    By:   /s/ Craig L. Slutzkin
      Craig L. Slutzkin
    Its:   Chief Financial Officer
    NEW LEAF BIOPHARMA OPPORTUNITIES II, L.P.
    By:   New Leaf BPO Associates II, L.P.
    Its:   General Partner
    By:   New Leaf BPO Management II, L.L.C.
    Its:   General Partner
    By:   /s/ Craig L. Slutzkin
      Craig L. Slutzkin
    Its:   Chief Financial Officer


    CUSIP No. 75120L100   13G

     

    NEW LEAF BPO ASSOCIATES II, L.P.
    By:   New Leaf BPO Management II, L.L.C.
    Its:   General Partner
    By:   /s/ Craig L. Slutzkin
      Craig L. Slutzkin
    Its:   Chief Financial Officer
    NEW LEAF BPO MANAGEMENT II, L.L.C.
    By:   /s/ Craig L. Slutzkin
      Craig L. Slutzkin
    Its:   Chief Financial Officer
    *
    Ronald Hunt
    *
    Vijay Lathi
    *By:   /s/ Craig L. Slutzkin
    Name:   Craig L. Slutzkin
      Attorney-in-Fact

    [*This Schedule 13G was executed by Craig L. Slutzkin on behalf of the individuals listed above pursuant to Powers of Attorney. Note that copies of the applicable Powers of Attorney are already on file with the appropriate agencies.]

    Get the next $RLYB alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RLYB

    DatePrice TargetRatingAnalyst
    4/9/2025Buy → Neutral
    H.C. Wainwright
    5/15/2024Overweight → Neutral
    JP Morgan
    2/7/2024$7.00 → $1.50Buy → Hold
    Jefferies
    4/17/2023$18.00Buy
    H.C. Wainwright
    4/10/2023$17.00Outperform
    Wedbush
    12/9/2022$21.00Overweight
    JP Morgan
    2/22/2022$32.00Mkt Outperform
    JMP Securities
    8/23/2021$40.00Outperform
    Evercore ISI Group
    More analyst ratings

    $RLYB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Rallybio Corporation

      SC 13G/A - Rallybio Corp (0001739410) (Subject)

      11/12/24 10:34:15 AM ET
      $RLYB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Rallybio Corporation

      SC 13G - Rallybio Corp (0001739410) (Subject)

      7/30/24 9:06:36 PM ET
      $RLYB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Rallybio Corporation

      SC 13G/A - Rallybio Corp (0001739410) (Subject)

      7/30/24 12:47:55 PM ET
      $RLYB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RLYB
    Financials

    Live finance-specific insights

    See more
    • Rallybio Announces Preliminary Phase 1 Multiple Ascending Dose Data for RLYB116, an Innovative Subcutaneously Injected Inhibitor of Complement Component 5

      -- 100 mg Results Demonstrated a Mean Reduction of Greater than 93% in Free C5 with Low Volume Once-a-Week Subcutaneous Dosing -- -- Data Supports the Study of RLYB116 as a Differentiated Therapeutic for the Treatment of Generalized Myasthenia Gravis -- -- Company Announces Extension of Runway to 3Q 2025 As Part of Portfolio Prioritization -- -- Conference Call and Webcast Today at 8:30 AM Eastern Time -- Rallybio Corporation (NASDAQ:RLYB) today announced preliminary Phase 1 multiple ascending dose (MAD) data for RLYB116, an innovative, long-acting, low volume subcutaneously injected inhibitor of complement component 5 (C5), in development for patients with complement-mediated disea

      12/20/23 8:00:00 AM ET
      $RLYB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RLYB
    SEC Filings

    See more
    • SEC Form S-8 filed by Rallybio Corporation

      S-8 - Rallybio Corp (0001739410) (Filer)

      5/9/25 4:06:03 PM ET
      $RLYB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Rallybio Corporation

      10-Q - Rallybio Corp (0001739410) (Filer)

      5/8/25 8:22:09 AM ET
      $RLYB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rallybio Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Rallybio Corp (0001739410) (Filer)

      5/8/25 8:14:12 AM ET
      $RLYB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RLYB
    Leadership Updates

    Live Leadership Updates

    See more
    • Rallybio Announces Succession Plan; Appoints Stephen Uden, M.D., as Chief Executive Officer, Effective August 1, 2023

      -- Martin Mackay, Ph.D., CEO, Chairman of the Board and Co-Founder of Rallybio To Become Executive Chairman -- Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced that Stephen Uden, M.D., Rallybio's President, Chief Operating Officer and Co-Founder has been appointed to the role of Chief Executive Officer, effective August 1, 2023. Dr. Uden will remain President and will also be appointed to Rallybio's Board of Directors. The Company does not expect to hire a replacement for Dr. Uden's current role. He will succeed Mart

      6/29/23 7:00:00 AM ET
      $RLYB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rallybio Reports Fourth Quarter and Full Year 2022 Financial Results

      -- Proof-of-Concept Achieved for RLYB212; Showed Rapid and Complete Elimination of Transfused HPA-1a Positive Platelets in HPA-1a Negative Subjects -- -- Phase 1 Multiple Dose Cohort RLYB212 Study Initiated -- -- Phase 1 Multiple Ascending Dose Study of RLYB116 Continues to Progress; Safety, PK and PD Data Expected in 4Q 2023 -- -- $169.0 million cash, cash equivalents and marketable securities as of December 31, 2022; Provides Runway into 1Q 2025 -- Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today reported financial results

      3/6/23 8:00:00 AM ET
      $RLYB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rallybio Announces Appointment of Jonathan I. Lieber as Chief Financial Officer

      Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced that Jonathan I. Lieber will join as the Company's Chief Financial Officer (CFO), effective February 1, 2023. Mr. Lieber succeeds Jeffrey Fryer, CPA, Rallybio's Co-Founder and CFO. The company announced Mr. Fryer's departure in June 2022, and following a transition period with Mr. Lieber, Mr. Fryer will depart the company on February 15, 2023. Mr. Lieber brings more than 30 years of experience as a CFO for public and private life sciences companies and an investment ban

      1/31/23 4:05:00 PM ET
      $RLYB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RLYB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Rallybio downgraded by H.C. Wainwright

      H.C. Wainwright downgraded Rallybio from Buy to Neutral

      4/9/25 8:36:28 AM ET
      $RLYB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rallybio downgraded by JP Morgan

      JP Morgan downgraded Rallybio from Overweight to Neutral

      5/15/24 7:39:44 AM ET
      $RLYB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rallybio downgraded by Jefferies with a new price target

      Jefferies downgraded Rallybio from Buy to Hold and set a new price target of $1.50 from $7.00 previously

      2/7/24 6:42:56 AM ET
      $RLYB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RLYB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Executive Officer Uden Stephen

      4 - Rallybio Corp (0001739410) (Issuer)

      2/19/25 7:30:54 PM ET
      $RLYB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Medical Officer Ryder Steven

      4 - Rallybio Corp (0001739410) (Issuer)

      2/19/25 7:29:06 PM ET
      $RLYB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Financial Officer Lieber Jonathan I

      4 - Rallybio Corp (0001739410) (Issuer)

      2/19/25 7:27:18 PM ET
      $RLYB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RLYB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Rallybio Reports First Quarter 2025 Financial Results and Provides Business Updates

      – On Track to Initiate Dosing in RLYB116 Confirmatory PK/PD Study in 2Q 2025, with Multiple Data Readouts Anticipated in 2H 2025 – – $54.5 Million in Cash, Cash Equivalents, and Marketable Securities as of March 31, 2025 Provides Runway into 1H 2027 – Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today reported first quarter financial results for the period ended March 31, 2025, and provided an update on recent company developments. "We are focused on advancing RLYB116 into a confirmatory pharmacokinetic/pharmacodynamic study this quarter, and believe th

      5/8/25 8:00:00 AM ET
      $RLYB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rallybio to Present at the 2025 Citizens JMP Life Sciences Conference

      Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced that Stephen Uden, M.D., Chief Executive Officer of Rallybio, will participate in a fireside chat at the Citizens JMP Life Sciences Conference on Wednesday, May 7, 2025 at 12:00 p.m. ET in New York, NY. A live webcast of the fireside chat will be accessible through the Events and Presentations section of Rallybio's website at www.rallybio.com. An archived replay of the webcast will be available for 30 days following the presentation. About Rallybio Rallybio (NASDAQ:RLYB) is a clinical-stage bi

      4/29/25 8:00:00 AM ET
      $RLYB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rallybio to Discontinue Development of RLYB212 for Prevention of FNAIT

      – RLYB212 Phase 2 PK Results Did Not Achieve Target Concentrations, Including Minimum Target Concentration Required for Efficacy – – RLYB116 Confirmatory PK/PD Study to Initiate in 2Q 2025, with Data in 2H 2025 – Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced the discontinuation of the RLYB212 program for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT). The Company's decision to discontinue RLYB212 development was based on pharmacokinetic (PK) data from the Phase 2 clinical trial demonstrating the inability of the R

      4/8/25 8:00:00 AM ET
      $RLYB
      Biotechnology: Pharmaceutical Preparations
      Health Care